Brief: Ose Immunotherapeutics Says First Patient Randomized In Phase 2 Trial Evaluating Tedopi® With Opdivo®

Ose Immunotherapeutics SA

17/11/2021 06:42

Nov 17 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * ANNOUNCE WITH FORT FOUNDATION THAT FIRST PATIENT
RANDOMIZED IN
PHASE 2 CLINICAL TRIAL EVALUATING TEDOPI® IN COMBINATION WITH
OPDIVO® (NIVOLUMAB) IN NON-SMALL CELL LUNG CANCER
    * CLINICAL TRIAL SPONSORED AND CONDUCTED BY THE ITALIAN
ONCOLOGY
FOUNDATION FORT AND SUPPORTED BY BRISTOL MYERS SQUIBB AND OSE
IMMUNOTHERAPEUTICS
    * WE ARE EXPECTING FIRST RESULTS OF TEDOPI® AS A POTENTIAL
SECOND-LINE TREATMENT OF NSCLC PATIENTS AFTER
CHEMO-IMMUNOTHERAPY IN 2024-CEO
    * A STRATEGY OF COMBINING OPDIVO®, A PD-1 TARGETED
CHECKPOINT
INHIBITOR, WITH TEDOPI® AS A SECOND-LINE TREATMENT IN PATIENTS
WITH METASTATIC NON-SMALL CELL LUNG CANCER AFTER FIRST-LINE
CHEMO-IMMUNOTHERAPY

Source text for Eikon:  ID:nBw1dKbZZa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))